Table 4.

Overall Survival of the Studied Group in Relation to Prognostic Factors

	n	n events	Cumulative survival proportion (%)	Median survival (months)	p-value
All cases	75	46	47.8	10 (4-16)
Age group
Children	37	23	50.2	12.6 (1.2-24.0)	0.951
Adults	38	23	45.6	10.1 (3.5-16.7)
Sex
Male	56	33	54.2	13.8 (6.5-21.0)	0.249
Female	19	13	28.5	6.4 (3.0-9.9)
Immunophenotype
B/myeloid	60	35	51.5	12.6 (6.0-19.2)	0.292
T/myeloid	15	11	33.3	5.5 (1.6-9.3)
BCR::ABL1
Positive	10	4	58.3	*	0.412
Negative	65	42	46.4	8.0 (2.5-15.7)
KMT2A-r
Yes	3	3	0	2.1 (0.2-4.0)
No	72	43	49.8	10.8 (5.3-16.3)	0.001
Cytogenetics (n=37)
Normal	4	3	50	6.4 (0.0-30.8)	0.684
Abnormal	33	17	50.1	15.4 (0.0-31.6)
Ch.21 abn. (n=37)
Yes	15	6	64.6	*
No	22	14	40	4.1 (0.0-10.5)	0.131
CTH
Myeloid	58	38	46.3	10.1 (3.7-16.5)	0.131
Lymphatic	17	8	52.9	*
Imatinib
Yes	11	5	51.1	*
No	64	41	47.1	10.1 (2.5-17.7)	0.36
BMT
Yes	5	0	100	*
No	70	46	44.2	*	0.027

*, Median survival cannot be calculated; BMT, Bone marrow transplantation